Digistain at ESMO Congress 2023 Berlin

We are presenting a poster at the ESMO Breast Cancer Annual Congress (#ESMOBreast23) from 11-13 May in Berlin. The poster demonstrates that the Digistain Prognostic Score showed high accuracy and predictive performance, and stratified patients with early breast cancer into low or high risk.  The low cost, rapidity and accessibility of Digistain’s technology approach has potential as an alternative or addition to existing prognostic tools across real-life clinical practice, including under-resourced settings.  

Supported by:

royal society logo
NIHR logo
cancer research uk logo
BIVDA logo

Subscribe to leading news and insights

To stay updated about Digistain’s developments, enter your details opposite. We promise only to send you important news.